Treatment of Congenital Syphilis in South Africa
For newborns with proven or highly probable congenital syphilis in South Africa, use aqueous crystalline penicillin G 100,000-150,000 units/kg/day IV (given as 50,000 units/kg/dose every 12 hours for the first 7 days of life, then every 8 hours) for 10 days, OR procaine penicillin G 50,000 units/kg IM once daily for 10 days. 1
Treatment Algorithm Based on Clinical Scenario
The treatment approach depends critically on maternal treatment history and the infant's clinical status:
Scenario 1: Proven or Highly Probable Congenital Syphilis
When the mother was not treated, inadequately treated, has no documentation of treatment, received non-penicillin therapy (like erythromycin), or was treated <4 weeks before delivery, the infant requires:
Preferred regimens 1:
- Aqueous crystalline penicillin G 100,000-150,000 units/kg/day IV, divided as 50,000 units/kg every 12 hours (first 7 days), then every 8 hours (days 8-10)
- OR Procaine penicillin G 50,000 units/kg IM once daily for 10 days
Critical evaluation needed 1:
- CSF analysis (VDRL, cell count, protein)
- CBC with differential and platelet count
- Long-bone radiographs
Important caveat: If you use single-dose benzathine penicillin G (50,000 units/kg IM), the infant must have a completely normal evaluation with certain follow-up. If any part is abnormal, uninterpretable (blood-contaminated CSF), or not performed, you must switch to the 10-day penicillin course 1.
Scenario 2: Lower Risk Situations
When the mother was adequately treated >4 weeks before delivery with appropriate penicillin therapy for her stage of infection, and shows no evidence of reinfection/relapse, and the infant has:
- Normal physical examination
- Nontreponemal titer ≤4-fold the maternal titer
Treatment: Benzathine penicillin G 50,000 units/kg IM as a single dose 1
Alternatively, close serologic follow-up without treatment is acceptable if maternal titers decreased fourfold after early syphilis treatment or remained stable/low for late syphilis 1.
Scenario 3: Minimal Risk
When the mother had adequate treatment before pregnancy and maintained low, stable titers throughout pregnancy (VDRL <1:2; RPR <1:4), and the infant has normal examination with titers ≤4-fold maternal:
Treatment: No treatment required, though benzathine penicillin G 50,000 units/kg IM may be considered if follow-up is uncertain 1
South African Context Considerations
The South African data reveals critical challenges that make aggressive treatment particularly important 2, 3:
- High mortality: 13-38% mortality reported in symptomatic CS cases in South African tertiary centers
- Poor antenatal care attendance: 19-56% of mothers with CS-affected infants had no antenatal care
- HIV co-infection: 52% of mothers with CS-affected infants were living with HIV (significantly higher than general population)
- Healthcare system failures: Poor notification, inadequate partner tracing, and failure to recheck serology after 32 weeks
Given these realities, err on the side of treatment rather than observation when follow-up is uncertain - a common scenario in South Africa where 19% of mothers in one study did not attend antenatal care 2.
Older Infants (≥1 month)
For children ≥1 month identified with congenital syphilis 1:
Treatment: Aqueous crystalline penicillin G 200,000-300,000 units/kg/day IV, given as 50,000 units/kg every 4-6 hours for 10 days
Required evaluation:
- CSF analysis
- CBC with differential and platelet count
- Long-bone radiographs, chest radiograph, liver function tests, abdominal ultrasound, ophthalmologic examination, auditory brainstem response as indicated
Evidence Quality Note
The Cochrane review confirms that evidence for CS treatment is sparse 4. However, low-quality evidence supports penicillin reducing clinical manifestations and increasing serological cure. High-quality evidence shows no difference between benzathine and procaine penicillin for outcomes, supporting either choice in the 10-day regimen 4.
The key principle: When in doubt, treat with the full 10-day course rather than single-dose therapy, especially given South Africa's documented high morbidity and mortality rates and challenges with follow-up.